Skip to content

Platelet rich plasma transplantation for the periodontal tissue defects

Exploratory clinical study to evaluate the safety of Platelet rich plasma transplantation for the periodontal tissue defects - Platelet rich plasma transplantation for the periodontal tissue defects

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030190277
Enrollment
2
Registered
2020-03-31
Start date
2019-03-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Interventions

Sponsors

Tobita Morikuni
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Have a Periodontal pocket more than 5 mm at baseline examination. 2) Intrabony defect is 5 mm and more depth, and 2 mm and more width at interproximal site of the experimental tooth by X-ray examination. 3) Already have received initial preparation at the screening. 4) Mobility of experimental tooth is 0, 1, or 2, and exist keratinized gingiva. 5) Persons whose oral hygiene is established Good oral hygiene. 6) 20 years and older. 7) Signed informed consent

Exclusion criteria

Exclusion criteria: 1) Can not be measured clinical attachment level of experimental tooth. 2) Have a history of Complicate malignant tumor. 3) Suspected of oral malignant tumor or precancerous lesion. 4) Need to undergo the treatment, such as surgical treatment, restorative treatment or root canal treatment, at the experimental tooth within 36 weeks after transplant. 5) Pregnancy, during breastfeeding, or possibility of pregnancy. 6) Persons who suffer from disorders of kidney, liver or blood 7) Have disease of kidney, liver and/or blood. 8) Have active infectious diseases. 9) Alcoholism or Drug dependence. 10) Mental or consciousness disorder. 11) HCV antibody, HBs antigen, ATLA virus antibody or HIV antibody positive person. 12) Smoke more than 10 pieces per day. 13) Have anti-coagulant or anti-platelet medications, or have a bleeding disorders. 14) Other,the investigator believes makes him/her unsuitable for participation in the clinical study.

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Efficacy

Countries

Japan

Contacts

Public ContactYosuke Masubuchi

Juntendo university

y-masubuchi@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026